Maxona Pharmaceuticals, Inc.
This is a single center, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of MAX-001 in participants with post-operative dental pain after wisdom teeth removal.
Screening will be conducted for up to 4 weeks prior to inpatient surgery (Day 1) and initiation of dosing (Day 1, Hour 0) with study drug. Dosing will continue through Hour 48. Participants who meet all inclusion criteria and none of the exclusion criteria will undergo extraction of bilaterally impacted mandibular third molar teeth oral surgery under local anesthesia. This extraction is required to involve a full or partial bony impaction confirmed by panoramic X-ray. Removal of any maxillary third molars, if necessary, is permitted but not required. Local anesthesia with lidocaine 2% with ep…
Inclusion Criteria: * Body mass index (BMI) between 18 to 35.0 kg/m\^2, inclusive * Scheduled to undergo elective bilateral mandibular third molar extraction under local anesthesia. This extraction has to involve a full or partial bony impaction confirmed by panoramic X-ray. * In good health and capable of undergoing oral surgery under the anesthesia protocol as described * No recent surgery within 2 months prior to Screening and no additional planned surgeries during the course of the study and for the 2 months following * No clinically significant abnormalities as determined by medical hist…
30 mg oral tablets
matching placebo
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.